Skip to main content
$127.01 -$2.27 (-1.8%)

04:00 PM EST on 03/08/21

NovoCure (NASDAQ:NVCR)

CAPS Rating: 5 out of 5

Current Price $127.01 Mkt Cap $13.2B
Open $127.77 P/E Ratio 647.17
Prev. Close $127.01 Div. (Yield) $0.00 (0.0%)
Daily Range $125.08 - $132.83 Volume 938,781
52-Wk Range $53.40 - $194.75 Avg. Daily Vol. 732,482

Caps

How do you think NASDAQ:NVCR will perform against the market?

Add Stock to CAPS Watchlist

All Players

330 Outperform
1 Underperform
 

All-Star Players

147 Outperform
1 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:NVCR Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

marekz (77.96)
Submitted October 07, 2020

Innovative cancer Tumor Treting Fields is really catching on with the booming cancer treatment field, and Wall Street is catching on finally. The stock is up 50% over the last few weeks, and doesn't look to taper off with late-stage clinical trials… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:NVCR VS S&P 500 (SPY)

NASDAQ:NVCR Summary

Fools bullish on NASDAQ:NVCR are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about NVCR.

Recs

0
Member Avatar Masakari (38.17) Submitted: 3/4/2021 1:41:25 PM : Outperform Start Price: $136.75 NASDAQ:NVCR Score: -9.15

This is a medical device company addressing a widespread disease with a proven product that is seeing increasing adoption throughout the medical community. Additionally, their pipeline appears robust and offers significant opportunity to expand their TAM moving forward.

Recs

0
Member Avatar TreasureCoastJLF (< 20) Submitted: 2/19/2021 11:55:04 AM : Outperform Start Price: $185.97 NASDAQ:NVCR Score: -29.08

Fighting cancer with physics. You have to go to the website, Novocure.com and read the investor .ppt which has a video. I am a physician and this technology is approved for Glioblastoma & Mesothelioma and is currently in late stage development (phase 3) for Liver Cancer, Ovarian Cancer, and Small Cell Lung Cancer. The pipeline is deep and will tremendously expand the # units in use.

Recs

0
Member Avatar Frogman452 (< 20) Submitted: 2/5/2021 3:38:18 PM : Outperform Start Price: $175.06 NASDAQ:NVCR Score: -26.01

I am pretty picky about my investments and most pitches I tune out pretty quickly. This is one of the few I can recall being instantly interested in both for its promising financials and more importantly for it's results in treating cancer. Seems almost like a sci-fi future company. Who else can do what they do? Such an easy stock to get behind.

Leaderboard

Find the members with the highest scoring picks in NVCR.

Score Leader

stcksrus

stcksrus (97.89) Score: +910.73

The Score Leader is the player with the highest score across all their picks in NVCR.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. stcksrus 97.89 7/27/2016 Outperform 5Y $11.69 +986.48% +75.75% +910.73 0 Comment
synapse 98.03 10/20/2017 Outperform 5Y $18.25 +595.95% +48.70% +547.24 0 Comment
findil 95.36 10/23/2017 Outperform 5Y $18.43 +589.34% +48.45% +540.89 1 Comment
SuzyP99 80.43 8/23/2017 Outperform 1Y $18.75 +577.39% +56.23% +521.16 1 Comment
lorenzo404 42.19 1/15/2016 Outperform 3W $17.58 +622.47% +104.48% +517.99 0 Comment
kaderoundy 99.71 10/8/2015 12/28/2020 Outperform NS $17.98 +606.40% +91.87% +514.53 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. skyrocket29 67.58 8/22/2017 Outperform 1Y $19.10 +564.97% +56.72% +508.26 0 Comment
tprooney3 96.23 7/17/2017 Outperform 5Y $19.25 +559.79% +55.51% +504.29 1 Comment
XMFpessen 97.28 12/5/2017 Outperform 5Y $19.95 +536.80% +44.45% +492.35 0 Comment
TMFEBCapital 97.47 8/1/2017 7/28/2020 Outperform 3Y $19.70 +544.72% +54.38% +490.34 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NVCR.